[PDF] Committee for Medicinal Products for Human Use (CHMP) recommends approval of osilodrostat (Isturisa) for treatment of Cushing's syndrome

European Medicines Agency - EMA
European Medicines Agency
Publication date:
15 November 2019


Osilodrostat inhibits 11-beta-hydroxylase (CYP11B1), an enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland. The expected benefits include the ability to control or normalise raised cortisol levels in adults.